莫西沙星与头孢呋辛联用阿奇霉素治疗社区获得性肺炎的对照研究

目的 比较莫西沙星与头孢呋辛联用阿奇霉素治疗社区获得性肺炎的临床疗效和安全性.方法 将78例社区获得性肺炎患者,随机分为莫西沙星治疗组和头孢呋辛联用阿奇霉素对照组,观察两组患者临床疗效、细菌清除率及不良反应.结果 莫西沙星组40例患者,痊愈32例(80.0%),显效6例(15.0%),总有效率95.0%,细菌清除率89.0%,不良反应发生率7.5%,头孢呋辛联用阿奇霉素组38例患者,痊愈30例(78.9%),显效5例(13.2%),总有效率92.1%,细菌清除率84.0%,不良反应发生率7.9%.结论 莫西沙星与头孢呋辛联用阿奇霉素治疗社区获得性肺炎的临床疗效、细菌清除率及安全性差异无统计学意义.

Comparison of Moxifloxacin and Cefuroxime Combined with Azithromycin for Patients with Community-acquired Pneumonia

OBJECTIVE To evaluate the efficacy, the eradication rates of pathogens and safety of moxifloxacin in patients with community-acquired pneumonia (CAP) in comparison with therapy using a combination of cefuroxime plus azithromycin. METHODS Seventy eight patients with CAP were randomly divided into two groups:moxifloxacin alone and cefuroxime plus azithromycin, and the efficacy, the eradication rates of pathogens and the rates of side effects were observed. RESULTS From 40 patients in the moxifloxacin group, 32 patients (80%) were clinically cured and 6 patients (15 %)were improved. And from 38 patients in the cefuroxime plus azithromycin groups, 30 patients (78.9%) were clinically cured and 5 patients (13.2%) were improved. The eradication rates of pathogens were 89% and 84%, respectively. And the rates of side effects were 7.5% and 7.9%, respectively. CONCLUSIONS There are no significant differences in the efficacy, the eradication rates of pathogens and safety between 2 groups in treating community-acquired pneumonia.